Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

Melinda L TelliJennifer K LittonJ Thaddeus BeckJason M JonesJay AndersenLida A MinaRaymond BrigMichael DansoYuan YuanWilliam F SymmansJulia F HopkinsLee A AlbackerAntonello AbbattistaKay NoonanMarielena MataA Douglas LairdJoanne L Blum

Published in: Breast cancer (Tokyo, Japan) (2024)

The results from this exploratory biomarker analysis support the central role of BRCA and TP53 mutations in tumor pathobiology. Furthermore, these data support assessing germline BRCA mutational status for molecular eligibility for talazoparib in patients with TNBC.

Keyphrases

early stage
breast cancer risk
dna repair
rectal cancer
lymph node
electronic health record
dna damage
squamous cell carcinoma
machine learning
radiation therapy
artificial intelligence